Cytodiagnosis of Malignant Melanoma: Immunoperoxidase Staining with HMB-45 Antibody as an Aid to Diagnosis

Ae, Walts; Jw, Said; Ip, Shintaku

doi:10.1093/ajcp/90.1.77

Cited by 49 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Thanks to its high specificity, this antibody also appeared to be a useful marker for malignant melanoma cells in smears prepared from cytologic specimen. 15 HMB-45 immunoreactivity has also been reported in a rare variant of signet ring cell melanoma lacking a well-known marker of melanoma such as S-100 protein. 2 In this study we have demonstrated that 2% of breast carcinomas show HMB-45 immunoreactivity.…”

Section: Discussionmentioning

confidence: 96%

Breast Carcinoma with Positive Results for Melanoma Marker (HMB-45): HMB-45 Immunoreactivity in Normal and Neoplastic Breast

Bonetti

Colombari

Manfrin

et al. 1989

American Journal of Clinical Pathology

View full text Add to dashboard Cite

A MONOCLONAL ANTIBODY (HMB-45) has been described recently that recognizes (including on paraffin sections) a so-far undefined molecule(s) apparently restricted to melanocytes.5 ' 6In a previous work we have analyzed the distribution of HMB-45 in a large panel of melanocyte and nonmelanocytic tumors, confirming the specificity of this antibody for junctional melanocytes, melanomas, and histogenetically related tumors, such as melanocytic neuroectodermal tumor of infancy and, rarely, peripheral nerve sheath tumors. 4 Other workers have reported the positive reaction with HMB-45 of one of five neuroblastomas. 16 However, testing HMB-45 on numerous normal tissues, we have found an unexpected positive reaction in the epithelium of secretory terminal tract of sweat glands. 4 The possibility of a positive reaction of HMB-45 in epithelial tumors has thus been considered, despite the extremely high specificity for melanocytes so far reported for this antibody.We report here the presence of HMB-45 immunoreactivity in normal and neoplastic breast epithelium.

show abstract

Section: Discussionmentioning

confidence: 96%

Breast Carcinoma with Positive Results for Melanoma Marker (HMB-45): HMB-45 Immunoreactivity in Normal and Neoplastic Breast

Bonetti

Colombari

Manfrin

et al. 1989

American Journal of Clinical Pathology

View full text Add to dashboard Cite

show abstract

“…To analyze gene transfer efficiency, gp100 expression of DC was determined by immunohistochemistry staining with anti-gp100 mAb HMB-45 as previously described. 36 Briefly, cells were fixed and blocked and incubated for 1 h with the HMB-45 mAb (DAKO-HMB45, M634, Hamburg, Germany). Ag expression was detected by a second step Ab (DAKO) followed by ABC staining (DAKO).…”

Section: Recombinant Adenoviruses and Transduction Of DCmentioning

confidence: 99%

Priming of T cells with aAd-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy

Tuettenberg¹,

Jonuleit²,

Tüting³

et al. 2003

Gene Ther

View full text Add to dashboard Cite

In recent years, vaccination strategies using antigen-presenting cells (APC) have been under investigation. Antigen delivery using genetic immunization through ex vivo transduction of dendritic cells (DC) is supposed to enhance the induction of antitumor responses in humans by activating a broad range of peptide-specific CD8 + T cells. In this study, we compared the potential of adenoviral (Ad)-transduced versus peptide-pulsed DC to induce melanoma-antigen (Ag)-specific T-cell responses in vitro. Whereas gp100-peptidepulsed DC induced long-lasting specific CD8 + T-cell responses against single peptides, Ad-transduced DC induced broad and strong, specific immunity against various peptides of the gp100-Ag. Surprisingly, several restimulations led to decreasing gp100-specific and in parallel to increasing antiadenoviral T-cell responses. Nevertheless, those anti-adenoviral T-cell responses provided an 'adjuvant' effect by inducing an early release of high amounts of IL-2/IFN-g, therewith enhancing CTL induction in the initiation phase. Based on these data, we suggest a prime/boost vaccination strategy in melanoma patients -combining the use of Ad-DC and peptide-pulsed DC -to obtain efficient and long-term antitumor T-cell responses.

show abstract

“…Special stains that are relatively specific for melanoma, such as S-100 9 or HMB-45, 10 have been available for years, but their use has never been incorporated into the routine pathological examination of lymph node specimens. This is mainly because immunohistochemical analysis of all the nodes from a complete lymph node dissection, which typically involves 10 to 30nodes,wouldbeprohibitivelytime-consuming and expensive.…”

mentioning

confidence: 99%

Molecular Staging of Malignant Melanoma

Shivers

Wang²,

Li³

et al. 1998

JAMA

337

View full text Add to dashboard Cite

Context.-For most solid tumors, the metastatic status of regional lymph nodes is the strongest predictor of relapse and survival. However, routine pathological examination of lymph nodes may underestimate the number of patients with melanoma who have nodal metastases.Objective.-To determine the clinical significance of a highly sensitive molecular assay for occult nodal metastases for the staging of patients with melanoma.Design.-A prospective cohort study of consecutive patients in which lymphatic mapping and sentinel lymph node (SLN) biopsy were performed on 114 melanoma patients with clinical stage I and stage II disease. The SLNs were bivalved, and half of each specimen was submitted for routine pathological examination. The other half was submitted for molecular detection of submicroscopic metastases using a reverse transcriptase-polymerase chain reaction (RT-PCR) assay for tyrosinase messenger RNA as a marker for the presence of melanoma cells. Patient followup averaged 28 months.Setting.-A major university-based melanoma referral center at a National Cancer Institute-designated cancer center.Patients.-A total of 114 patients with newly diagnosed cutaneous malignant melanoma who were at risk for regional nodal metastases.Main Outcome Measure.-Melanoma recurrence and overall survival.Results.-Twenty-three patients (20%) had pathologically positive SLNs, and all of these patients were also RT-PCR positive. Of the 91 pathologically negative patients, 44 were RT-PCR negative and 47 were RT-PCR positive. There was a recurrence rate among 14 (61%) of the 23 patients who were both pathologically and RT-PCR positive and a recurrence rate among 1 (2%) of 44 patients who were both pathologically and RT-PCR negative. For patients who were upstaged by the molecular assay (pathologically negative, RT-PCR positive), there was a recurrence rate among 6 (13%) of 47 patients. The differences in recurrence rates and overall survival between the pathologically negative, RT-PCR-negative and pathologically negative, RT-PCR-positive patient groups were statistically significant (P = .02 for disease-free survival and for overall survival). In both univariate and multivariate regression analyses, the histological and RT-PCR status of the SLNs were the best predictors of disease-free survival.Conclusions.-The use of an RT-PCR assay for detection of submicroscopic melanoma metastases in SLNs improved the prediction of melanoma recurrence and overall survival over routine pathological examination.

show abstract

Cytodiagnosis of Malignant Melanoma: Immunoperoxidase Staining with HMB-45 Antibody as an Aid to Diagnosis

Cited by 49 publications

References 0 publications

Breast Carcinoma with Positive Results for Melanoma Marker (HMB-45): HMB-45 Immunoreactivity in Normal and Neoplastic Breast

Breast Carcinoma with Positive Results for Melanoma Marker (HMB-45): HMB-45 Immunoreactivity in Normal and Neoplastic Breast

Priming of T cells with aAd-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy

Molecular Staging of Malignant Melanoma

Contact Info

Product

Resources

About